Good evening :)
Place Order
Add to Watchlist

Gufic Biosciences Ltd

GUFICBIO Share Price

384.400.27% (-1.05)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹3,865 cr, stock is ranked 878

Stock is 3.06x as volatile as Nifty

GUFICBIO Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Bad

The stock is overpriced and in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹3,865 cr, stock is ranked 878

Stock is 3.06x as volatile as Nifty

GUFICBIO Performance & Key Metrics

GUFICBIO Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
55.507.260.03%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.086.540.76%

GUFICBIO Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

GUFICBIO Company Profile

Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.

Investor Presentation

View older View older 

May 30, 2025

PDF
View Older Presentations

GUFICBIO Similar Stocks (Peers)

Compare with peers Compare with peers 

GUFICBIO Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.40
37.40
1Y Return
6.23%
6.23%
Buy Reco %
84.85
84.85
PE Ratio
22.71
22.71
1Y Return
1.62%
1.62%
Buy Reco %
68.75
68.75
PE Ratio
62.06
62.06
1Y Return
15.14%
15.14%
Buy Reco %
70.83
70.83
PE Ratio
54.71
54.71
1Y Return
24.01%
24.01%
Buy Reco %
81.25
81.25
PE Ratio
18.59
18.59
1Y Return
5.70%
5.70%
Buy Reco %
48.39
48.39
Compare with Peers

GUFICBIO Forecast

GUFICBIO Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

GUFICBIO

GUFICBIO

Income

Balance Sheet

Cash Flow

GUFICBIO Income Statement

GUFICBIO Income Statement

Loading...

Financial YearFY 2024FY 2025TTM
Total Revenue808.85823.43823.43
Raw Materialssubtract389.32685.11685.11
Power & Fuel Costsubtract17.79
Employee Costsubtract109.63
Selling & Administrative Expensessubtract103.90
Operating & Other expensessubtract40.15
Depreciation/Amortizationsubtract17.0221.0621.07
Interest & Other Itemssubtract15.3623.1123.11
Taxes & Other Itemssubtract29.5424.4924.50
EPS8.596.956.94
DPS0.100.100.10
Payout ratio0.010.010.01

GUFICBIO Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 30PDF
Feb 14PDF
Nov 14PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 29PDF
Nov 11PDF
Aug 11PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF

Investor Presentation

Nov 11PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

GUFICBIO Stock Peers

GUFICBIO Past Performance & Peer Comparison

GUFICBIO Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Gufic Biosciences Ltd55.497.260.03%
Sun Pharmaceutical Industries Ltd37.405.640.94%
Cipla Ltd22.713.831.08%
Torrent Pharmaceuticals Ltd62.0615.630.91%

GUFICBIO Stock Price Comparison

Compare GUFICBIO with any stock or ETF
Compare GUFICBIO with any stock or ETF
GUFICBIO
Loading...

GUFICBIO Holdings

GUFICBIO Shareholdings

GUFICBIO Promoter Holdings Trend

GUFICBIO Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

GUFICBIO Institutional Holdings Trend

GUFICBIO Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

GUFICBIO Shareholding Pattern

GUFICBIO Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding72.51%3.39%0.00%0.31%23.79%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

GUFICBIO Shareholding History

GUFICBIO Shareholding History

Dec '23MarJunSepDec '24Mar0.47%0.12%0.23%0.24%0.30%0.31%

Mutual Funds Invested in GUFICBIO

Mutual Funds Invested in GUFICBIO

No mutual funds holding trends are available

Top 5 Mutual Funds holding Gufic Biosciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.3379%0.99%-0.13%46/59 (-7)
0.9419%0.95%0.01%30/34 (-1)
0.4149%0.19%-0.02%97/130 (0)

Compare 3-month MF holding change on Screener

GUFICBIO Insider Trades & Bulk Stock Deals

GUFICBIO Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing GUFICBIO stock

smallcases containing GUFICBIO stock

Looks like this stock is not in any smallcase yet.

GUFICBIO Events

GUFICBIO Events

GUFICBIO Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

GUFICBIO Dividend Trend

No dividend trend available

GUFICBIO Upcoming Dividends

GUFICBIO Upcoming Dividends

No upcoming dividends are available

GUFICBIO Past Dividends

GUFICBIO Past Dividends

Cash Dividend

Ex DateEx DateSep 17, 2024

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 17, 2024

Cash Dividend

Ex DateEx DateSep 21, 2023

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 21, 2023

Cash Dividend

Ex DateEx DateAug 24, 2022

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Aug 24, 2022

Cash Dividend

Ex DateEx DateSep 9, 2021

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 9, 2021

Cash Dividend

Ex DateEx DateNov 3, 2020

Final
Final | Div/Share: ₹0.05

Dividend/Share

0.05

Ex DateEx Date

Nov 3, 2020

GUFICBIO Stock News & Opinions

GUFICBIO Stock News & Opinions

Corporate
Gufic BioSciences appoints senior management personnel

Gufic BioSciences has appointed Rajesh Kaul as Senior President - Sparsh Cluster, Senior Management Personnel of the Company with effect from 04 July 2025. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Gufic BioSciences consolidated net profit declines 61.50% in the March 2025 quarter

Net profit of Gufic BioSciences declined 61.50% to Rs 7.72 crore in the quarter ended March 2025 as against Rs 20.05 crore during the previous quarter ended March 2024. Sales rose 5.14% to Rs 205.02 crore in the quarter ended March 2025 as against Rs 194.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 19.14% to Rs 69.65 crore in the year ended March 2025 as against Rs 86.14 crore during the previous year ended March 2024. Sales rose 1.63% to Rs 819.81 crore in the year ended March 2025 as against Rs 806.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales205.02194.99 5 819.81806.67 2 OPM %12.8717.55 -16.4318.08 - PBDT18.3731.46 -42 115.21132.69 -13 PBT10.5227.12 -61 94.14115.67 -19 NP7.7220.05 -61 69.6586.14 -19 Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Gufic BioSciences standalone net profit declines 60.25% in the March 2025 quarter

Net profit of Gufic BioSciences declined 60.25% to Rs 7.97 crore in the quarter ended March 2025 as against Rs 20.05 crore during the previous quarter ended March 2024. Sales rose 5.14% to Rs 205.02 crore in the quarter ended March 2025 as against Rs 194.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 18.82% to Rs 69.93 crore in the year ended March 2025 as against Rs 86.14 crore during the previous year ended March 2024. Sales rose 1.63% to Rs 819.81 crore in the year ended March 2025 as against Rs 806.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales205.02194.99 5 819.81806.67 2 OPM %12.9917.55 -16.4618.08 - PBDT18.6131.46 -41 115.48132.70 -13 PBT10.7727.12 -60 94.42115.68 -18 NP7.9720.05 -60 69.9386.14 -19 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Gufic BioSciences recommends final dividend

Gufic BioSciences announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Gufic BioSciences to announce Quarterly Result

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Gufic BioSciences standalone net profit declines 13.21% in the December 2024 quarter

Net profit of Gufic BioSciences declined 13.21% to Rs 19.32 crore in the quarter ended December 2024 as against Rs 22.26 crore during the previous quarter ended December 2023. Sales rose 2.98% to Rs 207.79 crore in the quarter ended December 2024 as against Rs 201.78 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales207.79201.78 3 OPM %16.3418.07 - PBDT30.9033.70 -8 PBT26.2829.56 -11 NP19.3222.26 -13 Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Gufic BioSciences to announce Quarterly Result

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live
Spotlight
Gufic Biosciences tumbles after Q2 PAT drops 6% YoY to Rs 22 cr

Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review. EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24. Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.Powered by Capital Market - Live

7 months agoCapital Market - Live
Spotlight
Gufic Biosciences Q2 PAT drops 6% YoY to Rs 22 cr

Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review. EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24. Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant. The scrip rose 1.95% o settle at Rs 446.65 on Thursday, 14 November 2024, the domestic stock market to remain closed today on account of Guru Nanak Jayanti.Powered by Capital Market - Live

8 months agoCapital Market - Live
Earnings
Gufic BioSciences standalone net profit declines 6.16% in the September 2024 quarter

Net profit of Gufic BioSciences declined 6.16% to Rs 21.78 crore in the quarter ended September 2024 as against Rs 23.21 crore during the previous quarter ended September 2023. Sales declined 4.98% to Rs 204.18 crore in the quarter ended September 2024 as against Rs 214.87 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales204.18214.87 -5 OPM %18.9218.32 - PBDT33.5735.24 -5 PBT29.2730.94 -5 NP21.7823.21 -6 Powered by Capital Market - Live

8 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Gufic Biosciences Ltd (GUFICBIO) today?

    The share price of GUFICBIO as on 18th July 2025 is ₹384.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Gufic Biosciences Ltd (GUFICBIO) share?

    The past returns of Gufic Biosciences Ltd (GUFICBIO) share are
    • Past 1 week: 7.77%
    • Past 1 month: 3.60%
    • Past 3 months: 11.86%
    • Past 6 months: -15.35%
    • Past 1 year: 9.72%
    • Past 3 years: 91.24%
    • Past 5 years: 335.09%

  3. What are the peers or stocks similar to Gufic Biosciences Ltd (GUFICBIO)?
  4. What is the dividend yield % of Gufic Biosciences Ltd (GUFICBIO) share?

    The current dividend yield of Gufic Biosciences Ltd (GUFICBIO) is 0.03.

  5. What is the market cap of Gufic Biosciences Ltd (GUFICBIO) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gufic Biosciences Ltd (GUFICBIO) is ₹3865.20 Cr as of 18th July 2025.

  6. What is the 52 week high and low of Gufic Biosciences Ltd (GUFICBIO) share?

    The 52-week high of Gufic Biosciences Ltd (GUFICBIO) is ₹504.25 and the 52-week low is ₹298.80.

  7. What is the PE and PB ratio of Gufic Biosciences Ltd (GUFICBIO) stock?

    The P/E (price-to-earnings) ratio of Gufic Biosciences Ltd (GUFICBIO) is 55.49. The P/B (price-to-book) ratio is 7.26.

  8. Which sector does Gufic Biosciences Ltd (GUFICBIO) belong to?

    Gufic Biosciences Ltd (GUFICBIO) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Gufic Biosciences Ltd (GUFICBIO) shares?

    You can directly buy Gufic Biosciences Ltd (GUFICBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.